Certolizumab Pegol
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Certolizumab Pegol
- Pharmacist Assessment Report
- Certolizumab pegol: PEGylated anti-TNF-alpha antibody fragment → hypermobility of coccyx
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Certolizumab pegol: PEGylated anti-TNF-alpha antibody fragment → hypermobility of coccyx
One-Sentence Summary
Certolizumab pegol (Cimzia) is a PEGylated antigen-binding fragment of a monoclonal antibody that neutralises tumour necrosis factor alpha (TNFα), and it is currently marketed in Australia. The TxGNN model predicts it may be relevant to hypermobility of coccyx, with a score of 0.9975. No clinical trials and no publications in the data compiled for this report support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypermobility of coccyx |
| TxGNN Prediction Score | 0.9975 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Certolizumab pegol is generally described as an anti-TNFα agent. TNFα is a central driver of inflammation in immune-mediated conditions.
Hypermobility of the coccyx is mainly a mechanical or structural problem of the tailbone. No plausible TNF-mediated mechanism has been established for it. The link between this drug and this condition therefore rests on the model’s score alone. Neither mechanistic data nor any study supports it, and the similarity to the drug’s established uses has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 10137M | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | Not recorded in the local data |
The product is a single-ingredient injectable, and the licence is currently valid.
Safety Considerations
Product-specific warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.
Drug Interactions (100 interaction records were identified; the first 20 are summarised here):
- Major: systemic and other corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone including the ophthalmic form), deferiprone, ibritumomab tiuxetan, iobenguane (I-131) and tositumomab (I-131).
- Moderate: metronidazole, tinidazole, pegvaliase, rosuvastatin and simvastatin.
- Minor: zinc salts (acetate, gluconate, sulfate).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (0.9975), but there are no registered trials and no literature on this condition. No TNF-mediated mechanism is established for a mechanical or structural condition of the coccyx. The evidence level is L5.
To proceed, the following is needed:
- A plausible mechanistic rationale linking TNFα inhibition to coccyx hypermobility, with mechanism of action data for the drug.
- Preclinical or clinical studies that directly address this condition.
- Review of the TGA-approved Product Information for warnings and contraindications.
- Assessment of route and dosage-form suitability for the proposed use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.